Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
114 words
A process for purifying a proteinaceous physiologically active substance having antitumor activity, the formation of which physiologically active substance is induced by administering to a rabbit at least one substance having a capacity for stimulating reticuloendothelial system and then injecting endotoxin from a Gram-negative bacterium into the rabbit, which process comprises (1) contacting a crude solution of said physiologically active substance with a basic anion exchanger to have said physiologically active substance adsorbed on the anion exchanger, (2) eluting the adsorbed physiologically active substance, and (3) subjecting the eluate containing said physiologically active substance to gel filtration with a gel suitable for separation of a substance with a molecular weight of 30,000 to 70,000.
Claim 2
Dependent Claim
114 words
A process for purifying a proteinaceous physiologically active substance having antitumor activity, the formation of which physiologically active substance is induced by administering to a rabbit at least one substance having a capacity for stimulating reticuloendothelial system and then injecting endotoxin from a Gram-negative bacterium into the rabbit, which process comprises (1) contacting a crude solution of said physiologically active substance with a basic anion exchanger to have said physiologically active substance adsorbed on the anion exchanger, (2) eluting the adsorbed physiologically active substance, and (3) subjecting the eluate containing said physiologically active substance to gel filtration with a gel suitable for separation of a substance with a molecular weight of 30,000 to 70,000.
Claim 3
Dependent Claim
35 words
A process according to claim 1 wherein the crude solution is contacted with the basic anion exchanger, using a buffer solution of pH 6.0 to 9.0 and salt concentration of not more than 0.2 M.
Claim 4
Dependent Claim
24 words
A process according to claim 1 or 2 wherein the eluent employed in gel filtration is a buffer solution of pH 6.0 to 9.0.
Claim 5
Dependent Claim
144 words
A proteinaceous physiologically active substance, the formation of which is induced by administering to a rabbit at least one substance having a capacity for stimulating reticuloendothelial system and then injecting endotoxin from a Gram-negative bacterium into the rabbit, having the following characteristic properties: a) Molecular weight : 39,000 + 5,000; b) Isoelectric point : pH 3.9 + 0.3; c) Mobility in cellulose acetate electrophoresis (pH 8.6) : 10 4 to 10 -6 cm 2 / V .sec; d) Specific activity according to the biological evaluation using L cell as defined in the specification : at least 0.5 x 10 9 units/mg-protein; and , e) Activity according to the biological evaluation using transplanted Meth A sarcoma in (BALB/c x C57BL/6)F 1 mouse as defined in the specification, when administered intravenously at a dose corresponding to 0.1 to 1 ng protein per mouse: (+) or higher.
Claim 6
Dependent Claim
144 words
A proteinaceous physiologically active substance, the formation of which is induced by administering to a rabbit at least one substance having a capacity for stimulating reticuloendothelial system and then injecting endotoxin from a Gram-negative bacterium into the rabbit, having the following characteristic properties: a) Molecular weight : 39,000 + 5,000; b) Isoelectric point : pH 3.9 + 0.3; c) Mobility in cellulose acetate electrophoresis (pH 8.6) : 10 4 to 10 -6 cm 2 / V .sec; d) Specific activity according to the biological evaluation using L cell as defined in the specification : at least 0.5 x 10 9 units/mg-protein; and , e) Activity according to the biological evaluation using transplanted Meth A sarcoma in (BALB/c x C57BL/6)F 1 mouse as defined in the specification, when administered intravenously at a dose corresponding to 0.1 to 1 ng protein per mouse: (+) or higher.
Claim 7
Dependent Claim
47 words
An aqueous solution of a proteinaceous physiologically active substance purified by a process as claimed in claim 1, 2 or 3, optionally containing an isotomic agent and/or a buffering agent, for use in parenteral or topical administration in the treatment of malignant tumors in mammals including humans.